Headaches
TRIUMPH: Treatment of Migraine Outcomes for Patients in Real-World Healthcare Systems
In Progress but Closed for Enrollment
The overall aim is to estimate real-world effectiveness and associated outcomes, as well as describe treatment patterns, in patients with migraine in routine clinical care who are switching or initiating pharmacologic treatment for migraine prevention. The primary comparison of interest is between galcanezumab and oral standard of care. However, patients who are initiating other CGRP monoclonal agents or botulinum toxin A or B will also be eligible to participate in the study and are included in the descriptive and statistical comparisons as sample sizes permit.